IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Position Increased by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 13.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 5,857,639 shares of the company's stock after buying an additional 695,263 shares during the period. Janus Henderson Group PLC owned 6.78% of IDEAYA Biosciences worth $150,606,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new stake in IDEAYA Biosciences during the fourth quarter valued at about $13,385,000. FMR LLC raised its stake in shares of IDEAYA Biosciences by 2.6% in the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock valued at $333,153,000 after acquiring an additional 327,498 shares during the period. Vanguard Group Inc. lifted its holdings in shares of IDEAYA Biosciences by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock valued at $130,507,000 after acquiring an additional 282,936 shares in the last quarter. WCM Investment Management LLC purchased a new stake in IDEAYA Biosciences during the 4th quarter worth $6,030,000. Finally, Adage Capital Partners GP L.L.C. raised its position in IDEAYA Biosciences by 22.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,200,094 shares of the company's stock valued at $30,842,000 after purchasing an additional 220,000 shares during the period. Institutional investors and hedge funds own 98.29% of the company's stock.

Analyst Ratings Changes

Separately, Stephens restated an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, IDEAYA Biosciences presently has an average rating of "Moderate Buy" and an average price target of $54.27.

IDEAYA Biosciences Stock Performance

Shares of IDEAYA Biosciences stock traded up $0.51 during trading on Friday, hitting $17.82. 1,150,677 shares of the stock were exchanged, compared to its average volume of 997,541. The stock's fifty day moving average is $17.65 and its 200 day moving average is $22.35. The stock has a market cap of $1.56 billion, a PE ratio of -5.40 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 12 month low of $13.45 and a 12 month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the company posted ($0.53) EPS. Sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.